Oppenheimer Asset Management Inc. Sells 2,691 Shares of Avantor, Inc. (NYSE:AVTR)

Oppenheimer Asset Management Inc. lessened its position in Avantor, Inc. (NYSE:AVTR) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 93,139 shares of the company’s stock after selling 2,691 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Avantor were worth $2,410,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of AVTR. Swedbank AB acquired a new stake in shares of Avantor during the first quarter worth about $2,707,000. Sound Shore Management Inc. CT bought a new stake in Avantor during the 2nd quarter worth approximately $76,412,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Avantor by 18.5% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 353,687 shares of the company’s stock worth $9,044,000 after buying an additional 55,129 shares during the period. Seven Eight Capital LP bought a new position in Avantor in the second quarter valued at approximately $642,000. Finally, New York State Teachers Retirement System acquired a new position in shares of Avantor in the third quarter valued at approximately $8,473,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Stock Performance

Shares of AVTR opened at $20.74 on Friday. The company has a market cap of $14.12 billion, a PE ratio of 45.09, a price-to-earnings-growth ratio of 2.61 and a beta of 1.35. The firm has a 50-day moving average of $24.52 and a 200-day moving average of $24.01. Avantor, Inc. has a one year low of $19.11 and a one year high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Insider Activity at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Wells Fargo & Company dropped their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. UBS Group dropped their price target on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Morgan Stanley upped their price objective on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Stifel Nicolaus lifted their target price on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Finally, Barclays cut their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.57.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.